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Non-viral integrating systems, PhiC31 phage integrase (φC31), and Sleeping Beauty transposase (SB), provide an eﬀective method
for ex vivo gene delivery into cells. Here, we used a plasmid-encoding GFP and neomycin phosphotransferase along with
recognition sequences for both φC31 and SB integrating systems to demonstrate that both systems eﬀectively mediated integration
in cultured human ﬁbroblasts and in rat multipotent adult progenitor cells (rMAPC). Southern blot analysis of G418-resistant
rMAPC clones showed a 2-fold higher number of SB-mediated insertions per clone compared to φC31. Sequence identiﬁcation
of chromosomal junction sites indicated a random proﬁle for SB-mediated integrants and a more restricted proﬁle for φC31
integrants. Transgenic rMAPC generated with both systems maintained their ability to diﬀerentiate into liver and endothelium
albeit with marked attenuation of GFP expression. We conclude that both SB and φC31 are eﬀective non-viral integrating systems
for genetic engineering of MAPC in basic studies of stem cell biology.
1.Introduction
Stem cells are capable of long-term self-renewal in culture
and can be induced to form a variety of cell types. These
characteristics provide a unique resource for genetic and
developmental studies or for therapeutic use in the develop-
mentofcellandgenetherapies.Multipotentadultprogenitor
cells (MAPC) represent a class of stem cells derived from
bone marrow (BM) and other adult mammalian tissues that
can be expanded in culture [1–3] to generate multiple cell
types in vitro and in vivo [4–8]. Several transplantation
studieshavedemonstratedthathumanMAPCsarebeneﬁcial
for functional recovery following vascular ischemia possibly
via trophic eﬀects [9–12] and possess contact-independent
immunosuppressive potential [13, 14]. These properties
suggest that MAPCs may be an eﬀective source for potential
use in immunomodulation and in the treatment of ischemic
diseases. Further extension of its use in single-gene disorders
and for use in creation of cell-based screening models
requires methods to engineer MAPC by introduction of
deﬁned genetic elements.
Non-viral DNA-mediated gene transfer has been ex-
plored as a means of expressing new genes in a variety of
diﬀerent cell types in vitro and in vivo. However, the useful-
ness of naked DNA vectors is often restricted by the inability
to provide sustained gene expression. Stable integration of2 Stem Cells International
the plasmid-encoded sequence is ineﬃcient, as it relies on
random double-strand break-mediated recombination. One
methodofaddressingthisproblemistousenon-viralvectors
in conjunction with a recombinase that has the capability of
integrating genetic cargo into cellular chromosomes.
Sleeping Beauty (SB) transposase and PhiC31 (φC31)
integrase are plasmid-based systems that have been demon-
strated to mediate stable gene transfer and expression in
mammalian cells. SB is a member of the Tc1/mariner-like
family of DNA transposons, which are found as inactive
remnants throughout various genomes in all of the major
kingdoms except bacteria and mediate gene transfer by a
“cut-and-paste” mechanism [15]( Figure 1). The SB trans-
poson system was generated by “repairing” an evolutionarily
decayedTc1-likesequencefoundinthegenomesofsalmonid
ﬁsh [16]. The autonomous element consists of the catalytic
transposase ﬂanked by inverted terminal repeats (ITRs) each
containing two direct repeats (DR), which are binding sites
for the transposase and essential for transposition [16, 17].
For gene transfer applications, the transposase is separated
from the transposon ends and replaced with any DNA cargo.
Thetransposasecanbesuppliedonthesame(cis)orseparate
(trans) plasmid from the one encoding the transposon or
as in vitro transcribed mRNA [18]. When expressed, the
transposase excises the transposon from the donor plasmid
and precisely inserts this genetic element into vertebrate
chromosomes at a TA dinucleotide. In contrast to random
recombination, insertion mediated by transposition occurs
without altering the ﬂanking chromosomal sequence. The
SB transposon system has been used for stable genetic
modiﬁcation of multiple rodent and human cell lines [16,
17, 19] and primary cells including mouse liver [20–25],
human skin cells [26], mouse lung [27–29], and human
peripheral blood T-cells [30]a sw e l la se m b r y o n i cs t e m
(ES) cells derived from mice [31, 32] and humans [33, 34].
Murine MAPC modiﬁed using an SB transposon engineered
for expression of a dual reporter encoding DsRed2 and
ﬁreﬂy luciferase have been used to study the homing
pattern of MAPC via in vivo bioluminescence imaging after
transplant into immunodeﬁcient mice [35]. Furthermore,
recent studies have demonstrated the usefulness of the SB
transposonsystemforgeneticmodiﬁcationofhumanCD34+
hematopoietic progenitor cells isolated from cord blood [36,
37].
The φC31 integrase is a member of the serine recom-
binase family found in Streptomyces [38]. Under natural
conditions, the two-component φC31 system mediates a
unidirectional recombination event between the attP site
of the phage genome and the attB site of the Streptomyces
chromosome. For applications in mammalian cells, gene
sequences on an attB containing plasmid are inserted into
cellular chromosomes at sites having partial homology to the
wild-type phage attP sequence (“pseudo-attP” sites) when
codelivered with a source of the phage integrase enzyme
[39, 40]( Figure 1). The frequency of PhiC31-mediated
integration is about 10- to 100-fold higher when compared
to the reversible recombinases (Cre and FLP) both of which
require that the target recognition sequence be preinserted
into the genome [41]. The utility of the φC31 system for
mediating stable gene expression has been demonstrated in
various cultured mammalian cell lines [42], and in primary
cells, including mouse liver [43, 44], human skin cells [45],
and muscle-derived stem cells [46] as well as for site-speciﬁc
genomic insertion in mouse [47] and human ES cells [48].
Here, we directly tested these two non-viral integrating
vectorsystemsforthecapacitytomediatestablegenetransfer
into primitive adult stem cells. An internally controlled,
bifunctional plasmid was utilized to codeliver recognition
sequences for both φC31 and SB integrating systems. We
investigated the frequency of gene insertion, strength of
gene expression, and the eﬀect of genetic modiﬁcation on
the stem cell potential of MAPC. These results provide
an assessment of the relative usefulness of these non-viral
integrating systems for the purpose of ex vivo gene transfer
andameanstogenerateintegratedengineeringplatformsfor
non-viral delivery and expression of transgenes in stem cells.
2.MaterialsandMethods
2.1. Plasmid Construction. The integrating vector (pKT2/
NAG) was constructed using T2 inverted terminal repeat
sequences ﬂanking the cargo [49]. For construction of
pKT2/NAG, the neomycin phosphotransferase (Neo) cDNA
was obtained by PCR using pT/Neo [50] as a template
with primers Neo-F (5 -GCC ACC ATG ATT GAA CAA
GAT GGA TTG C-3 )a n dN e o - R( 5  -CGC TCA GAA GAA
CTC GTC AAG AAG-3 ), and subsequently cloned into
pCR2.1-TOPO (Invitrogen, Carlsbad, Calif, USA) to form
pTOPO-Neo. An EcoRI fragment containing the ampliﬁed
Neo sequence was inserted into the polylinker between
the PGK promoter and rabbit β-globin polyadenylation
signal of pKT2/PGK to form pKT2/PGK-Neo. The attB
sequence and EF1α regulated GFP coding sequence was
created by introducing a 307-bp EcoR1 fragment containing
the φC31 attBs i t ef r o mp T A - attB[ 39], kindly provided by
Dr. Michele Calos, Stanford University) into the same site in
plasmid pVITRO-GFP (Invivogen, San Diego, Calif, USA). A
HindIII-XhoI fragment containing the attB sequence, EF1α
promoter, GFP coding sequence, and SV40 polyadenylation
signal was subsequently isolated and cloned upstream of the
PGKpromoterinpKT2/PGK-NeobetweenHindIIIandSalI.
The luciferase (pCMV-Luc) and SB10 transposase
(pCMV-SB) expression vectors have been previously
described [50, 51]. φC31 integrase was placed under tran-
scriptionalcontroloftheCMVpromoterbyisolatingaNheI-
SpeI fragment containing the integrase coding sequence
from pTOPO-Int (kindly provided by Dr. Michele Calos,
Stanford University) and cloning it in place of luciferase
in pCMV-Luc between NheIa n dXbaI. Plasmid DNA was
prepared using an Endofree Maxi Prep Kit (Qiagen, Valencia,
Calif, USA).
2.2. Cell Culture and Gene Transfer. Human ﬁbrosarcoma
HT1080 cells were maintained in complete growth medium
consisting of Dulbecco’s modiﬁed Eagle medium supple-
mented with 10% fetal bovine serum and 1% antimycotic-
antibiotic (Invitrogen, Carlsbad, Calif, USA), and incubated
at 37◦C in a humidiﬁed atmosphere containing 5% CO2.Stem Cells International 3
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Figure 1: Schematic diagram of the internally controlled pKT2/NAG vector and integration products mediated by Sleeping Beauty (SB)
transposase and by bacteriophage PhiC31 (φC31) integrase. (a) The integrating vector consists of (i) a φC31 integrase recognition site
(attB); (ii) eF1α or CMV- (Pr-) regulated GFP expression unit; (iii) neomycin resistance gene (Neo) transcriptionally regulated by the PGK
promoter; (iv) ﬂanking T2 transposase binding sites (IR/DRs; boxes with double triangles) separated by; (v) a colE1 bacterial origin of
replication and kanamycin resistance gene; (vi) pA, polyadenylation signal from the rabbit beta globin gene. (b) SB transposase-mediated
integration (left): the SB transposase excises transposon sequences at IR/DR transposase binding sites and precisely inserts them into TA-
dinucleotide targets in cellular chromosomes, which are subsequently duplicated. φC31 integrase-mediated integration (right): exogenous
gene sequences on an attB containing plasmid integrate into mammalian genomes at “pseudo-attP” sites, chromosomal sequences having
partial homology to the wild-type phage attP sequence.
The day before transfection, 4-5 × 105 cells were seeded
into 6-cm tissue culture plates. Cells were cotransfected
with pKT2/NAG (500ng) plus pCMV-Luc, pCMV-SB, or
pCMV-Int (150, 500, or 1500ng) using SuperFect reagent
(Qiagen, Valencia, Calif, USA) in a ﬁnal volume of 1mL
complete growth medium for three hours before changing
the medium. For stable gene transfer, cells were collected
two days after transfection, stained with trypan blue, and
counted. Viable cells (30,000) were plated into 100-mm
dishes containing complete growth medium supplemented
with 850μg/mL G418 (Invitrogen, Carlsbad, Calif, USA).
After 14 days of selection, cells were ﬁxed and stained with
a 70% methanol solution containing 1% crystal violet.
Rat MAPC (rMAPC) were maintained on ﬁbronectin
coated ﬂasks or dishes using previously described conditions
[52]. On the day of transfection, rMAPC were released from
plates with trypsin, washed with PBS, and 0.1 to 0.5 ×
106 viable cells (trypan blue negative) were resuspended in
nucleofection solution V (Amaxa, Gaithersburg, Md, USA)
with pKT2/NAG (5μg) and an equal amount of either
pCMV-Luc, pCMV-SB, or pCMV-Int, transferred into the
supplied cuvette, and electroporated (Amaxa; setting A-23)
as described earlier [52, 53]. The cells were immediately
resuspended in prewarmed growth medium and seeded into
6cm plates. For stable transfection, cells were grown in
medium supplemented with G418 (400μg/mL) 1 day after
transfection.
2.3. Flow Cytometry. HT1080 cells or MAPC were harvested
andrendered into single-cell suspensions forﬂow cytometric
analysis. Live cells were identiﬁed and gated by exclusion of
propidium iodide and then tested for expression of GFP on
a FACSCalibur System (Beckton-Dickinson) using CellQuest
analysis software (BD Biosciences, Heidelberg, Germany).
2.4. Southern Hybridization Analysis. Southern blotting was
performed as previously described [44]. Brieﬂy, 10μgo f
genomic DNA isolated from several G418-resistant MAPC
clones was digested overnight with BamHI (SB-treated cells)
or SpeI( φC31-treated cells), electrophoresed through 0.8%
agarose gel, and then blotted onto nytran. An 835-bp
fragment encoding the GFP sequence was isolated from
the integrating vector (pKT2/NAG) by AgeI-HindIII digest
and 32P radio-labeled using the Prime-It II Random Primer
Labeling Kit (Stratagene, La Jolla, Calif, USA) to use as the
DNA probe.
2.5. In Vitro Diﬀerentiation and Marker Expression. Undif-
ferentiated rMAPC that were unmanipulated, had gone
through random integration upon cotransfection with the
luciferase expression vector or stable integration mediated
by φC31integrase or SB transposase were harvested for
RNA isolation and RT-PCR analysis was carried out as
previously described [52]. The rMAPC were diﬀerentiated4 Stem Cells International
into endothelium or hepatocytes as described [2, 6, 7].
For endothelial diﬀerentiation, transgenic MAPC were cul-
tured in basal growth medium supplemented with 2% or
5% serum plus vascular endothelial growth factor (VEGF,
10ng/mL). Liver diﬀerentiation was elicited by addition of
2% serum, hepatocyte growth factor (HGF, 20ng/mL), and
ﬁbroblast growth factor-4 (FGF4, 10ng/mL) to the growth
medium. At days 9 and 14, cells were harvested for RNA iso-
lation, and end-stage RT-PCR or qRT-PCR analysis was per-
formed using primers for endothelium-speciﬁc transcripts
vascularendothelialgrowthfactorreceptor-2(Flk1),vascular
endothelial growth factor receptor-1 (Flt1), and endothelial-
derived gene-1 (Eg1) or hepatocyte-speciﬁc markers hep-
atocyte nuclear factor-3-beta (HNF3b), alpha-fetoprotein
(AFP), and transthyretin (Ttr), where glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) served as an internal
control for RNA loading and integrity. Amplicons from end-
stage RT-PCR were separated by electrophoresis through
2% agarose gel. For qRT-PCR, target gene expression was
normalized to GAPDH and relative expression calculated by
the 2−ΔΔCT formula. Primer sequences described in earlier
studies were used [6, 7]. All experiments were performed at
least in duplicate with technical replicates in each set.
2.6. Cytogenetic Analysis. Transgenic rMAPC were washed
to remove dead cells and resuspended in 10mL culture
medium. Cells were sent to the University of Minnesota
Cytogenetics Core Laboratory for analysis. Brieﬂy, cells
were treated with colcemid for 3 hours and then harvested
according to standard cytogenetic protocol. Approximately
100 metaphases were evaluated by G-banding at a 400–425
band level resolution.
2.7. Recovery of Integration Sites. G418-resistant clones
were isolated after cotransfection of each cell type with
pKT2/NAG plus pCMV-Luc, pCMV-SB, or pCMV-Int.
Genomic DNA (gDNA) was isolated using the Puregene
DNA puriﬁcation kit (Gentra Systems, Minneapolis, Minn,
USA). A genomic recovery method was used for identiﬁ-
cation of PhiC31 integrase-mediated chromosomal inser-
tions. High molecular weight DNA (2μg) was digested
with NheI, SpeI, and XbaI( w h i c hg e n e r a t ec o m p a t i b l e5  
termini; schematically represented in Figure 1) precipitated
in 100% ethanol and the recovered DNA was ligated under
dilute conditions (500μL) with 4 units of T4 DNA ligase
(New England BioLabs, Beverly, Mass, USA). The ligated
DNA was precipitated with 100% isopropanol, pelleted by
microcentrifugation and washed with 70% ethanol before
being resuspended in 10μL of sterile H2O. Two microliters of
this DNA was electroporated into DH10B electrocompetent
E. coli (Promega, Madison, Wis, USA), allowing bacterial
cells to recover in SOC media by incubation with agitation
at 37◦C/200rpm for 1 hour before plating on Luria/Bertania
agar containing 50μg/mL kanamycin. Plasmid DNA was
isolated and sequenced using primers that ﬂank the attB
site (shown in Figure 1(b)): attB-F (5 -TAG GGC GAA
AGG AAG GG TGG-3 )a n dattB-R (5 -GGC TTC GAG
ACC GTG ACC TA-3 ). For SB-mediated integration events,
a linker-mediated PCR technique was used to recover
transposon-chromosome junction sequences as described
[54] and schematically represented in Figure 1.G e n o m i c
DNA (2μg) was digested with BfaI and ligated to a linker.
Primary PCR was performed with primers 5 -GTA ATA
CGA CTC ACT ATA GGG C-3  and 5 -CTG GAA TTT
TCC AAG CTG TTT AAA GGC ACA GTC AAC-3  under
the following conditions: 94◦C for 2min, then 25 cycles of
94◦C for 15sec, 60◦C for 30sec and 72◦C for 90sec. The
PCR products were diluted and nested PCR was carried
out under the same conditions using primers 5 -AGG GCT
CCG CTT AAG GGA C-3  and 5 -GAC TTG TGT CAT
GCA CAA AGT AGA TGT CC-3 . The products of the
nested reaction were separated by electrophoresis through
2% agarose gel. Speciﬁc products were excised, puriﬁed
usingtheQiaquickgelextractionkit(Qiagen,Valencia,Calif,
USA), and cloned into pGEM-T vector (Promega, Madison,
Wis, USA) using ElectroMax DH10B (Invitrogen, Carlsbad,
Calif, USA) for transformation. All recovered integration
events were sequenced at the Advanced Genetics Analysis
Center at the University of Minnesota and subjected to
BlastN analysis against the rat genome using the ENSEMBL
database.
3. Results
3.1. Gene Transfer and Stable Expression in Cultured Human
Fibroblasts. The SB and φC31 recombinases each require
their own unique recognition sequence and catalytic com-
ponent to mediate the insertion of gene sequences into
chromosomes. We directly compared the eﬀectiveness of
integration and long-term expression using a single two-
component plasmid that is internally controlled for the inte-
grating sequence (Figure 1(a)). The mode of integration into
the host genome catalyzed by SB and φC31 is represented in
Figure 1(b).
To functionally test our internally controlled vector
(pKT2/NAG) when cotransfected with each recombinase, we
performed a colony-forming assay in cultured human male
ﬁbrosarcoma HT1080 cells. This cell line was selected on
the basis of a relatively normal karyotype by cytogenetic
analysis (46, XY, with 5p+ and 11q+) [55]. The eﬀect of
the dose of the codelivered recombinase-encoding plasmid
on stable gene transfer and expression was determined
by G418-resistant colony formation and GFP ﬂuorescence.
pKT2/NAG (500ng) was cotransfected in triplicate with 150,
500, or 1500ng of either CMV-regulated luciferase (pCMV-
Luc), transposase (pCMV-SB), or integrase (pCMV-Int)
expression plasmids (Figure 2(a)). Flow cytometric analysis
of GFP expression two days later demonstrated nearly
equivalent transfection eﬃciencies (20%–25% of cells were
GFP positive; data not shown). Similar to previous studies
[20, 50, 56], our data revealed the inhibitory eﬀect that is
frequently observed with increasing doses of transposase-
encoding plasmid. The lowest dose of pCMV-SB10 (150ng)
yielded the greatest increase (20-fold greater than the no
transposase control) in G418-resistant colony formation,
while the highest dose (1500ng) produced only 5-fold more
colonies than the no transposase control (Figure 2(b)). ForStem Cells International 5
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Figure2:StableexpressionmediatedbySBtransposaseandφC31integraseinculturedhumanﬁbroblasts.(a)Schematicdiagramofplasmids
cotransfected into HT1080 cells in a colony-forming assay. The integrating vector (pKT2/NAG) is described in Figure 1. Recombinase-
encoding plasmids are transcriptionally regulated by the cytomegalovirus immediate early promoter (CMV). The ﬁreﬂy luciferase encoding
expression vector (Luc) serves as a control for colony formation resulting from random recombination compared to stable gene transfer
mediated by SB transposase (SB) or φC31 integrase (Int). (b) Colony-forming assay for integration eﬃciency. HT1080 cells (4-5 × 105)
were cotransfected in triplicate with pKT2/NAG (500ng) and 150ng, 500ng, or 1500ng of Luc, SB, or Int encoding expression plasmids as
described in Section 2. The number of G418-resistant colonies per 3 × 104 cells plated is shown for each group (n = 3). Values are reported
as mean ± SE. (c) GFP expression in transgenic HT1080 cells. Examples of ﬂow cytometry plots are shown for unmanipulated HT1080 cells
(left panel; GFP negative) or an expanded G418-resistant clone (right panel; GFP positive). (d) Percentage GFP-positive cells determined by
ﬂow cytometric analysis of 10 independent G418-resistant clones expanded from HT1080 cells cotransfected with pKT2/NAG and 500ng
(open circle) or 1500ng (ﬁlled circle) of Luc, SB, or Int expression vectors. Mean percentages of GFP-positive cells for each condition are
indicated by solid lines.
φC31 integrase, increasing the concentration of pCMV-
Int improved G418-resistant colony formation (from 3- to
7-fold) compared to the no integrase control pKT2/NAG
(Figure 2(b)).
Ten G418-resistant clones generated by cotransfection
with 500ng or 1500ng of SB transposase or φC31 integrase
were independently expanded in G418-containing medium
for an additional four weeks to characterize expression of
the upstream GFP reporter by ﬂow cytometry (Figures 2(c)
and 2(d)). Three drug-resistant clones generated by random
recombination (+ pCMV-Luc) showed expression of GFP (>
60%), but the majority failed to express GFP (6/10 <10%
GFP positive). In contrast, GFP expression was maintained
in all clones rendered drug-resistant by SB- or PhiC31-
mediated integration but with increased eﬃciency in cells
transfected with 500ng versus 1500ng of each recombinase.
These results indicate that the single bifunctional construct
in the presence of the appropriate recombinase can mediate
integration into the host genome resulting in persistent
transgene expression.
3.2. Non-Viral Integration Eﬃciency and Stable Gene Expres-
sion in MAPC. Bone marrow-derived stem cells with the
capacity for self-renewal and proliferation in culture are6 Stem Cells International
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Figure 3: Non-viral integration eﬃciency in MAPC. Nucleofected rMAPC were plated and the medium was supplemented with G418
(400μg/mL) one day later. (a) Colony-forming assay. After 10–12 days of growth under selective conditions, cells were ﬁxed and stained to
determine the frequency of G418-resistant colony formation. The number of G418-resistant colonies (n = 3) for each group is shown ±
S.D. (b) Cells were harvested into a suspension and viable cell counts were performed by trypan blue exclusion on the indicated days and the
total number of cells in culture is reported as mean ± SE. (c) Genomic DNA isolated from the individual clones obtained with SB and Int
was subjected to restriction enzyme digestion, plasmid sequence rescue, and sequencing of the recovered fragment carried out to determine
the genomic site of integration.
important biological tools for studying cell fate and diﬀer-
entiation. To determine the integration eﬃciency mediated
by SB transposase (SB) and φC31 integrase (Int) in adult
stemcells,weevaluatedstablegenetransferinMAPCderived
from the bone marrow of newborn rat (postnatal days 2–5).
Nucleofection was used as the method of gene transfer based
onpreviousstudiesdemonstratingeﬃcientgenetransferand
low toxicity in these cells [52, 53].
The integrating vector pKT2/NAG was codelivered with
a source of recombinase at a 1:1 mass ratio (a dose
demonstrated to eﬀectively render HT1080 cells resistant to
G418 selection) into undiﬀerentiated MAPC using Amaxa
Nucleofector technology (described in Section 2.2), where
transfection eﬃciency ranged from 15% to 20% by ﬂow
cytometric analysis of GFP positive cells 24 hours later (data
not shown). After 7 to 10 days of growth in culture,we foundStem Cells International 7
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Figure 4: MAPC maintain their stem-cell character and the ability to diﬀerentiate following genetic engineering. (a) Karyotypic analysis of
pooled G418-resistant cells; the number of mitotic spreads containing the number of chromosomes indicated on the abscissa is indicated.
Absence of aneuploid or diploid cells indicates no gross karyotypic anomalies or aberrant cell-cycle activity in the analyzed cells. (b)
MAPCs are small spindle-shaped cells that are cultured at very low density. Morphological changes following diﬀerentiation into liver and
endothelium for two weeks as described in Section 2 show signiﬁcant diﬀerence between cells LUC-, Int- or SB-treated cells. (c) RT-PCR
analysis of the diﬀerentiated cells shows the presence of alpha-fetoprotein (AFP) and transthyretin (TTR) for liver diﬀerentiation, and
vascular endothelial growth factor receptor-1 (Flt1) and endothelial-derived gene-1 (Eg1) for diﬀerentiation into endothelium. Rat liver was
used as a positive control for liver and endothelial markers and undiﬀerentiated MAPC used as the negative control.
that G418-resistance was increased over background by 30-
fold for SB and 10-fold for Int when MAPC were allowed
to form distinct colonies (Figure 3(a)) or when pooled drug
resistant clones were subcultured to maintain the cell density
between 100–500cells/cm2 (Figure 3(b)) .T h e s ec l o n e sw e r e
expanded for further analysis including determination of
genomic integration site (Figure 3(c)).
3.3. Transgenic MAPC Maintain the Ability to Diﬀerentiate.
The eﬀect of genetic engineering on the karyotype of MAPC
was evaluated at the cytogenetic level for G418-resistant
pooled clones that were maintained at a density of 100–
500cells/cm2. The majority of the spreads (>80%) were
diploid with a normal karyotype for unmanipulated rat cells
as well as cells that had gone through random integration
upon cotransfection with the luciferase expression vector
or stable integration mediated by φC31integrase or SB
transposase (Figure 4(a)).
MAPC are characterized by the capacity to diﬀerenti-
ate into multiple cells types. Cells engineered for G418-
resistance using the control Luc, SB transposase, or PhiC31
integrase were maintained in culture under reduced serum
(2–5%) and in the presence of vascular endothelial growth
factor (VEGF) or ﬁbroblast growth factor 4 (FGF4) plus
hepatocyte growth factor (HGF). Following 14 days of dif-
ferentiation, distinct changes in the morphology of spindle-
shaped MAPC were observed. No signiﬁcant diﬀerence in
the morphology between Luc, SB, and Int was apparent8 Stem Cells International
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Figure 5: Stability of gene expression in MAPC. (a) Percentage GFP positive cells determined by ﬂow cytometric analysis of 24 independent
G418-resistant clones expanded from MAPC cotransfected with pKT2/NAG and Luc, SB, or Int expression vectors. Mean percentages of
GFP+ cells for each condition are indicated by black bars. (b) Southern hybridization analysis of SB- and φC31-mediated integration events.
Top shows a schematic representation of the 6709 bp circular plasmid nucleofected into rat MAPC and the location of the GFP probe. See
legend of Figure 1 for explanation of sequence elements contained in the vector. SpeIa n dBamHI restriction sites were used for digestion of
high molecular weight genomic DNA isolated from each G418-resistant clone. The SpeI site is located 2.4kb from the breakpoint in the attB
site. The BamHI site is located 3.5kb from the right IR/DR. The bottom ﬁgure shows the hybridization image of genomic DNA digested
with SpeI( φC31) and BamHI (SB) hybridized with the GFP probe. Clone number is indicated across the top, and marker positions are
indicated along the sides. (c) Flow cytometry of representative stable G418-resistant clones exhibiting GFP expression in HT1080 human
ﬁbroblasts and rat multipotent adult progenitor cells (rMAPCs) with integrating vector alone (left panel), integrating vector plus φC31
integrase (middle panel) and integrating vector plus SB transposase (right panel) compared to mock transfected cells of each type (black).
(d) FACS analysis of individual clones was also measured and the average %GFP+ cells determined. Bar graph showing the average GFP%
expression in HT12080 (dark bars) and rMAPC (light bars). Error bars represent standard deviation.
(Figure 4(b)). To further quantify and compare the diﬀeren-
tiation levels between the diﬀerent methods, both end point
RT-PCR and qRT-PCR analyses of RNA isolated from these
cells were positive for expression of endothelium (Flk-1,
Flt1, and Eg1) or hepatocyte (HNF3b, AFP, and TTR)
speciﬁc markers (Figure 4(c) and Table 1). These results
demonstrate that MAPC genetically engineered using SB or
φC31 maintain their stem-cell character and their ability to
diﬀerentiate into multiple cellular lineages upon induction.
3.4. Strength of Gene Expression in MAPC. The strength
of gene expression was determined for the GFP reporter.
Twenty-four drug-resistant clones were randomly isolated
for both SB and φC31 that had been expanded in G418-
containing medium for an additional 3-4 weeks. The levels
of GFP expression were determined for each independent
c l o n eb yﬂ o wc y t o m e t r y( Figure 5(a)). Although all of the
clones were G418 resistant, GFP intensity of most clones
was low with only a few percentage of the cells exhibitingStem Cells International 9
Table 1: qRTPCR analysis of diﬀerentiated rMAPC. Endothelium markers Flk1, Flt1, and Eg1 and liver markers HNF3b, AFP, and TTR were
measured and Ct values normalized to GAPDH levels to determine ΔCt. Adult rat liver was used as the positive control and corresponding
undiﬀerentiated cells as negative control. Relative expression was carried out by determining ΔCt values and comparing expression levels to
the positive control sample.
FIk1 FIt1 Eg1
ΔCt SD Rel Exp ΔCt SD Rel Exp ΔCt SD Rel Exp
MAPC 20.13 4.95 0.00006 15.23 11.81 0.00071 4.46 0.7 0.23982
Luc 8.34 0.35 0.22298 2.42 0.69 5.09824 1.79 0.69 1.52626
Int 10.13 0.15 0.0647 2.61 0.34 4.46915 2.28 0.33 1.08673
SB 8.84 0.63 0.15822 2.46 0.06 4.95883 1.8 0.13 1.51572
Adult rLiver 6.18 1.23 1 4.77 0.45 1 2.4 0.1 1
HNF3b AFP TTR
ΔCt SD Rel Exp ΔCt SD Rel Exp ΔCt SD Rel Exp
MAPC 3.27 0.21 1.38992 22.03 0.5 0 13.34 0.57 0
Luc 2.6 0.16 2.21914 16.42 0.32 0.0002 13.22 0.25 0
Int 2.51 0.14 2.35381 10.99 6.1 0.00867 3.95 1.96 0.0003
SB 1.78 0.35 3.90413 6.43 0.26 0.20448 1.95 0.2 0.0012
Adult rLiver 3.75 0.22 1 4.14 0.15 1 neg7.76 0.09 1
HNF3b: hepatocyte nuclear factor-3-beta; AFP: alpha-fetoprotein; TTR: transthyretin for liver diﬀerentiation, and Flk1: vascular endothelial growth factor
receptor-2; Flt1: vascular endothelial growth factor receptor-1; Eg1: endothelial-derived gene-1 for diﬀerentiation into endothelium. Total RNA isolated from
adult rat liver tissue (rLiver) was used as a positive control for liver and endothelial markers and undiﬀerentiated MAPC (MAPC) used as the negative
control.
expression above background. The clones were grouped
into three categories based on percentage (%) of cells
with GFP expression above background: low ≤5% GFP+;
intermediate: 10–20% GFP+;a n dh i g h≥20% GFP+. Using
these criteria, we found that the majority of the G418-
resistant clones contained a low or intermediate percentage
of GFP-expressing cells, including 23/24 clones generated by
random integration, 23/24 by PhiC31 integrase, and 18/24
by SB transposase, with only 1 of the SB-mediated clones
exhibiting signiﬁcantly higher levels of GFP expression.
To determine the eﬀect of each recombinase on integrant
copy number, we studied the average number of integrants
per MAPC clone by Southern blot analysis. Genomic DNA
isolated from 10 out of 24 randomly selected G418-resistant
MAPC clones was digested with enzymes that cut once
within the integrating vector sequence, generating GFP-
hybridizing fragments of varying size for each integrant and
providing an assessment of the number of stable insertions
mediated by SB transposase or φC31 integrase (Figure 5(b)).
The number of integrants among the SB-mediated stable
clones was 6 ± 3, with one G418-resistant clone (number 7)
showing at least 12 independent integrants. This value was
3-fold higher than previously described for SB10-mediated
insertions in cultured human ﬁbroblasts (1-2 transposon
integrants per clone) [50, 56, 57]. Interestingly, human
ﬁbroblasts with 1-2 genomic integrants per clone exhibited
stable gene expression, while MAPC with an increased
number of integrants showed weak transgene expression.
There were fewer integrants per clone in the case of φC31
integrase-mediated gene transfer (3 ± 1), likely resulting
from the site-preferred character of this vector system.
Interestingly, transgene expression in the MAPC clones
was signiﬁcantly lower compared to clones obtained with
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Figure 6: Chromosomal distribution of SB and φC31 integrants.
Integrants with ﬂanking sequence were recovered from the genome
of MAPC by either linker-mediated PCR (SB; grey bars) or plasmid
rescue (φC31; black bars); the frequency and distribution of
independent events is displayed.
the same construct in HT1080 (Figure 5(c)). Analysis of
average GFP+ cells in individual clones obtained in HT1080
and rMAPC further conﬁrm this observation (Figure 5(d)).
These results suggest either low copy number integration,
epigenetic suppression of the promoter-transgene elements
[58], or integration at a genomic site that does not support
active transcription.
3.5. Molecular Analysis of Integration Sites in Isolated MAPC
Clones. Several integrants were further characterized at the
sequence level using either linker-mediated PCR (SB) or
plasmid rescue (φC31) techniques (see Section 2.7). For SB,10 Stem Cells International
Table 2: φC31 and SB chromosome junction sequences recovered
from rat MAPC. Around 10 each of drug-resistant clones obtained
with PhiC31 integrase and SB transposase were chosen at random
to determine the site of genomic integration. Most clones showed
more than one integration event, consistent with southern blot
results. Exact genomic locations were determined by comparison
of the chromosomal junction sequence with that of the rat genome.
(a)
φC31 Integrase
Clone Chromosome band Location
1 4q42 158791838
9q22 51217205
2 2q44 236122145
9q22 51217122
15q11 58645720
17q12.1 57593447
3 2q26 141365031
3q21 51055488
7q13 32562140
15q12 66145915
20q12 4538590
4 2q34s 199022700
7q13 32562264
9q22 51217198
20q12 5244926
5 4q41 139277121
6q12 11098254
9q22 51217202
Xq12 18543448
6 17q12.1 57594096
Xq35 134407720
7 1q41 193493175
17q12.1 57593343
Xq35 134407720
8 1q41 193493175
9q22 51217207
9 17q12.1 57593353
(b)
SB Transposase
Clone Chromosome band Location
1 2q33 171779390
13q11 32001139
13q11 39927168
20q12 44445336
2 16p14 13906741
3 1p11 34991484
7q32 94455924
9q36 97344920
4 6q32 128228570
8q24 59559434
15q24 104110283
16q12.1 57613884
5 5q35 128927150
11q23 77290939
(b) Continued.
SB Transposase
Clone Chromosome band Location
6 3q35 102093005
4q22 59940513
4q23 71432455
5q35 134761715
16q12.2 60379119
7 6q13 23449543
17q11 49437069
8 7q12 16815756
8q24 77171774
9q11 7186249
9 9q36 90439317
12p12 2500679
10 2q11 6206693
5q21 48519577
7q13 28888887
10q26 75143457
Table 3: Correlation of GFP expression and integration site for
φC31 Integrase. Three clones were selected based on the expression
level of GFP (high, medium, or low). Plasmid rescue was carried
out to determine if the expression level correlated with integrant
number or genomic location.
Clone %GFP Chromosome band Position
Lo
<5%
<5%
<5%
5q12
17q12.1
Xq35
18035560
57593963
134407720
Med 10–20%
10–20%
1q41
17q12.1
193493175
57594096
Hi
>20%
>20%
>20%
>20%
8q31
10q31
17q12.1
Xq35
93775192
87259340
57594096
134407720
we recovered 30 unique transposon:chromosome junction
sequences that mapped to positions on 17 independent
chromosomes (Figure 6 and Table 2). We also obtained
27 distinct φC31 integrants that were distributed over 11
chromosomes (Figure 6 and Table 3). MAPC clones gen-
erated using SB exhibited a relatively random distribution
of integration, while φC31 treated MAPC revealed an
enrichment for speciﬁc sequences on chromosomes X, 9,
and 17 (Tables 2 and 4). As these sites were represented
in multiple independent clones, we decided to test three
clones demonstrating high, medium, or low GFP expression
with respect to integrant number and genomic location
(Table 3). This analysis revealed that neither the number
of integrants per clone nor the genomic location of the
integrantwasassociatedwithGFPexpressionlevel.Theclone
exhibitingahigherpercentageofGFP+ cellshad4integrants,
while clones characterized as having medium or low levels
of expression had 2 and 3 integrants each, respectively.
Furthermore, the clone demonstrating increased expression
of GFP (Hi) contained insertions on chromosomes X and 17
similar to the clone demonstrating reduced GFP expressionStem Cells International 11
Table 4: Hotspots for φC31-mediated integration in the genome
of rat MAPC. Nine drug-resistant clones and an additional three
clones picked on the basis of GFP expression were analyzed for
integrant number and genomic location. Of all the integration sites
identiﬁed, the location on chromosome 17 (17q12.1) was found to
be targeted with highest frequency (7 out of 12 clones) followed by
chromosome locations 9q22 (5 out of 12 clones) and Xq35 (4 out of
12 clones). Exact genomic location of the integrant and the nearest
genetothesiteofintegrationislistedforeachchromosomehotspot.
Chrom. Clone Chromosome
band Position Nearest
gene
17 2 17q12.1 57593447
6 57594096
7 57593343
9 57593353 ATI4B
59334046–59457079
Lo 57593962
Med 57594096
Hi 57594096
9 1 9q22 51217205
2 51217122
4 51217198 SDPR
47373044–47385061
5 51217202
8 51217207
X 6 Xq35 134407720
7 134407720
Xpnpep2
134474700–
134501921
Lo 134407720
Hi 134407720
(Lo), while integration on chromosome 9 was not detected.
Similarly, additionally analyzed clones with over 5 integrants
per cell did not exhibit high levels of GFP expression. These
data suggest that the number of integrants or the genomic
location of integrants alone may not dictate persistence in
expression of the transgene but a combination of these along
with other epigenetic factors could play a key determining
role.
4. Discussion
In this study, we used an internally controlled bifunctional
plasmid to deliver expression cassettes encoding GFP or
neomycin phosphotransferase along with both components
of the φC31 and SB integrating systems into cultured
human ﬁbroblasts and rat multipotent adult progenitor cells
(rMAPC). Both systems eﬀectively mediated stable gene
transfer resulting through recombinase-mediated integra-
tion of exogenous sequences. Genetically modiﬁed rMAPC
maintained their stem cell features, demonstrated by the
ability to diﬀerentiate into endothelium and liver tissues
in the presence of speciﬁc cytokines. Silencing of GFP was
observed for each system when G418-resistant rMAPC were
expanded in culture. Southern blot analysis demonstrated
that the number of integrants among the SB-transposed
stable clones was 6 ± 3 while fewer independent integrants
were detected for φC31 integrase engineered cell lines (3 ±
1).
Non-viral, DNA-mediated gene transfer has been
explored as a means of potential gene therapy targeting a
variety of diﬀerent cell types in vitro and in vivo. One long-
range goal is to test non-viral integrating vector systems for
the capacity to mediate stable, DNA-mediated gene transfer
in hematopoietic stem cells (HSC). Genetic engineering of
HSC with the capacity to complete long-term repopulation
of the hematopoietic system has previously been accom-
plished with the use of integrating viral vectors and has
been reported using the SB transposon system [36, 37].
Unlike HSC, MAPC are capable of long-term self-renewal
in culture and can be induced to diﬀerentiate with speciﬁc
cytokines to form multiple cell types. These characteristics
provide a unique resource for testing: (i) non-viral gene
transfer in primitive stem cells, (ii) the eﬀect of genetic
engineering on maintenance of the stem cell character, (iii)
stability of transgene expression following diﬀerentiation,
and (iv) insertion site proﬁles on a genome wide scale, with
the potential for functional screening in a primitive and
diﬀerentiating cell system.
Therapeutic application of stem cells for the correction
of genetic disorders will likely require long-term expression
of newly introduced therapeutic genes, most eﬀectively
accomplished by integration of the transgene. However,
along with the incorporation of exogenous elements into
chromosomal DNA comes the potential for adverse eﬀects
resulting from insertional mutagenesis. Integration could
lead to deregulated expression of tumor suppressor genes,
oncogenes, or cell-cycle regulatory genes resulting in cancer
[59–63]. As a result, genome-wide analyses of the insertion-
site preferences for integrating vectors are being explored in
a variety of target cells and tissues [60, 61, 64, 65].
SB transposons exhibit a relatively random integration
pattern in mammalian genomes [66–68]a n dm a yb el e s s
likely to integrate into transcribed genes or transcriptional
regulatory regions than other integrating vectors such as
retroviruses and lentiviruses [66, 67, 69]. Having a com-
parable gene transfer eﬃciency, φC31 integrase displays
preferenceforaseeminglylimitednumberofinsertiontarget
sites in mammalian genomes, beneﬁting from sequence
requirements of “pseudo attP” sites. In fact, analysis of
several φC31-mediated integration events suggests that pref-
erential sites for integration exist in both the mouse and
human genomes consistent with at most 30–40% partial
sequence homology to the wild-type phage attP target [20,
40, 42]. These data suggest that φC31 integrase-mediated
DNA insertion is a relatively site-preferred approach for
achieving persistent gene expression through integration.
A common limitation of viral or plasmid-based integra-
tion in undiﬀerentiated cells is gene silencing that occurs
during expansion or diﬀerentiation of the target population.
This quenching of expression is likely caused by epigenetic
eﬀects such as methylation of transcriptional regulatory
sequences or inhibition of transcription factor binding
through chromatin condensation and genome remodeling.12 Stem Cells International
Our results indicate that while SB transposase achieves
multiple integrations per clone, φC31 integrase mediates an
average of 2–4 integrations per clone. This is more than what
h a sb e e nr e p o r t e df o rm o u s ea n dh u m a nc e l l s( a na v e r a g eo f
1 integration site per clone [42, 43]) and could either be due
to the concentration of integrating plasmid used or the ratio
ofintegratingplasmidtoφC31integrase.Alternately,ratcells
in general or stem cells such as MAPC in particular might
have a more open chromatin structure, thus exposing more
“pseudo attP” sites for targeting by the PhiC31 integrase.
The only other study reporting successful use of PhiC31
integrase in rat cells was performed using the rat embryonic
ﬁbroblast cell line (Rat2) to ﬁrst identify preferential sites of
genomicintegration.Basedonthesepreferentialsites,aPCR-
based method was developed to characterize φC31-mediated
integrationeventsinretinalpigmentepithelialcellsfollowing
direct injection and subsequent in vivo electroporation [70].
From this methodology, three sites on chromosomes 12q16,
1q41, and 2q26 were determined to be preferential targets
with each displaying a limited level of sequence homology to
each other and with the φC31 attP site. Our results conﬁrm
the ﬁnding that preferential φC31 targets exist on 1q41
and 2q26 and extend this observation to identify three new
targets which represented a higher frequency of integration
events on chromosomes 17q12.1, 9q22, and Xq35. It is
possible that these genomic hotspots for PhiC31 integration
identiﬁed in rat MAPC are unique due to the nature of the
chromatin in these undiﬀerentiated cells.
5. Conclusions
We report here a relatively high eﬃciency of non-viral
modiﬁcation of MAPC using the SB transposon and the
PhiC31 phage integrase, where SB can be used to achieve
highergeneexpressionandPhiC31forfewerintegrationsites
but reduced expression levels. While both systems oﬀer an
alternative to viral methods of gene transfer into multipotent
adult progenitor cells as well as other types of stem cells,
still needed are comparative studies designed to characterize
maintenance of gene expression after diﬀerentiation.
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